Merck MRK has decided to stop the phase III HYPERION study early. The study evaluates MRK’s pulmonary arterial hypertension (PAH) drug, Winrevair (sotatercept), for a more advanced version of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback